Agrylin and Blood count abnormal - a phase IV clinical study of FDA data

Summary:

Blood count abnormal is reported as a side effect among people who take Agrylin (anagrelide hydrochloride), especially for people who are male, 60+ old, also take Jakafi, and have Polycythaemia vera.

The phase IV clinical study analyzes which people have Blood count abnormal when taking Agrylin. It is created by eHealthMe based on reports of 1,248 people who have side effects when taking Agrylin from the FDA, and is updated regularly.

What is Agrylin?

Agrylin has active ingredients of anagrelide hydrochloride. It is often used in primary thrombocythemia. eHealthMe is studying from 1,256 Agrylin users. Check the latest studies of Agrylin.

What is Blood count abnormal?

Blood count abnormal is found to be associated with 872 drugs and 702 conditions by eHealthMe. Check the latest studies of Blood count abnormal.

On Jul, 09, 2026

1,248 people reported to have side effects when taking Agrylin.
Among them, 13 people (1.04%) have Blood count abnormal.

Could Agrylin cause Blood count abnormal?

Among these 13 people:

What is the gender of people who have Blood count abnormal when taking Agrylin? *

female: 50 %
male: 50 %

What is the age of people who have Blood count abnormal when taking Agrylin? *

What are other drugs people take besides Agrylin? *

What are other side effects people have besides Blood count abnormal? *

Blood Urea Increased: 8 people, 61.54%
Haematocrit Decreased: 8 people, 61.54%
White Blood Cell Count Increased: 6 people, 46.15%
Neutrophil Count Increased (excess than normal number of neutrophil a type of blood cell): 6 people, 46.15%
Blood Alkaline Phosphatase Increased: 6 people, 46.15%
Blood Creatinine Increased: 6 people, 46.15%
Drug Intolerance (drug sensitivity): 6 people, 46.15%
Flatulence (flatus expelled through the anus): 6 people, 46.15%
Haemoglobin Decreased: 6 people, 46.15%
Head Injury: 6 people, 46.15%

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 10 people, 76.92%
Primary Myelofibrosis (primary disorder of the bone marrow): 7 people, 53.85%
Restless Leg Syndrome (a powerful urge to move your legs): 2 people, 15.38%
Migraine (headache): 2 people, 15.38%
High Blood Cholesterol: 2 people, 15.38%
Depression: 2 people, 15.38%
Polycythemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 1 person, 7.69%
Polycythaemia (proportion of blood volume that is occupied by red blood cells increases): 1 person, 7.69%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 7.69%
Essential Thrombocythaemia (chronic blood cancer): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Agrylin and have Blood count abnormal?

- Check whether Blood count abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Agrylin:

Agrylin (1,256 reports)

Browse all side effects of Agrylin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Blood count abnormal:

Blood count abnormal (872 drugs)

Browse all the conditions that are associated with Blood count abnormal:

Blood count abnormal (702 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on anagrelide hydrochloride (the active ingredients of Agrylin) and Agrylin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.